Avience Biomedicals IPO
Price band
₹196 – ₹208
Lot size
600 shares
Min investment
₹1,24,800
Issue size
₹30.24 Cr
IPO schedule
| Open date | 18 Jun 2026 |
| Close date | 22 Jun 2026 |
| UPI mandate cut-off | 22 Jun 2026 |
| Allotment finalisation | 23 Jun 2026 |
| Refund initiation | 24 Jun 2026 |
| Shares credited to demat | 24 Jun 2026 |
| Listing date | 25 Jun 2026 |
| Mandate end date | 7 Jul 2026 |
| Anchor lock-in (50%) | 22 Jul 2026 |
| Anchor lock-in (remaining) | 20 Sept 2026 |
Issue size
Grey Market Premium (GMP)
GMP is an unofficial, unregulated indicator and not a reliable predictor of listing price. Source: IPO Watch.
About Avience Biomedicals
Avience Biomedicals Limited is an Indian healthcare products company engaged in the manufacturing and supply of diagnostic kits, medical devices and related healthcare products. The company began its operations with diagnostic solutions such as Viral Transport Media (VTM) and test kits for diseases including COVID-19, HIV, HBsAg, malaria and dengue. Over time, it expanded its portfolio to include in-vitro diagnostic (IVD) rapid test kits, serology products, biochemistry analysers and biochemistry reagents. The company serves the healthcare sector by providing products used in disease detection, diagnosis and laboratory testing. Its revenue is primarily generated through the sale of these diagnostic and medical device products. Avience Biomedicals operates in the medical devices and diagnostics segment and focuses on offering healthcare solutions across multiple testing and diagnostic categories.
Strengths
- Manufactures a wide range of diagnostic kits, medical devices, analysers and reagents.
- Serves pathology labs, hospitals, research centres and other healthcare institutions.
- Holds ISO 9001, ISO 13485, GMP and ZED MSME Gold certifications.
- Operates a manufacturing facility in Noida with advanced processing capabilities.
- Has expanded from diagnostic kits to a broader portfolio of healthcare products.
Risks
- Business performance may be affected by changes in government policies and regulations.
- Operations depend on the continued services of key management personnel and employees.
- The company relies on third-party transportation and logistics providers.
- Market demand and industry fluctuations can impact revenue and profitability.
- The company has ongoing legal proceedings involving commercial and cheque dishonour matters.
IPO information is sourced from public feeds and shown for general information only. It is not a recommendation to apply for this or any IPO. IPOs are equity investments and carry market risk; listing gains are not guaranteed and SME IPOs are especially volatile. Grey Market Premium (GMP) is unofficial and not endorsed by SEBI or the exchanges. Equity IPOs are applied for through a demat and trading account, not through mutual fund distribution services. Read the RHP and consult a SEBI-registered investment adviser before investing.